Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATIS-ICAD: Rivaroxaban and Aspirin for Recurrent Ischemic Stroke Prevention
NCT04142125Phase 3Completed
- Sponsor
- Population Health Research Institute
- Start
- Feb 2020
- Primary completion
- Sep 2023
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in ischemic stroke, intracranial atherosclerotic disease (ICAD), sponsored by Population Health Research Institute. Started Feb 2020; status: completed.
02
Drugs
rivaroxaban
03
Conditions
ischemic strokeintracranial atherosclerotic disease (ICAD)
Beyond the preview
Go deeper on NCT04142125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142125.